Assignee
NAVROGEN INC
US·1 granted patent·3 pending applications·0 citations·filing 2020–2023
Top patents by PatentIndex Score
4 records- 0156US2026098858A1Fc-Engineered Monoclonal Antibodies Refractory to Tumor Immunosuppressive ICAM-1/CD54NAVROGEN INC·Filed 2023·Application pending·0 cites
- 0252US12516096B2Composition and use of humoral immune suppressor antagonists for the treatment of humoral immune suppressed diseasesNAVROGEN INC·Filed 2020·Granted Jan 6, 2026·0 cites·17 claims
- 0349US2023398232A1Composition and Use of Alternatively Formatted Anti-Mesothelin Antibodies for the Treatment of CancerNAVROGEN INC·Filed 2021·Application pending·0 cites
- 0449US2023203182A1Composition and Use of Engineered Monoclonal Antibodies Refractory to Tumor Immuno-Suppressive FactorsNAVROGEN INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when NAVROGEN INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →